Steady-state plasma concentrations of
clozapine and
norclozapine, its major metabolite, as well as their sum and ratio (
norclozapine/
clozapine), were evaluated in 50 in- and outpatients taking
clozapine and naturalistically recruited.
Drug plasma concentrations were measured by means of a reversed-phase high-performance liquid chromatography (RPLC) method with an ultraviolet detection. Daily doses (milligrams per kilogram of
body weight) of
clozapine correlated positively with
clozapine plasma parameters, except with the
norclozapine/
clozapine ratio, in all patients. When the patients were divided in subgroups with respect to gender, the corresponding plasma concentrations were no longer dose-related in men. A lack of significant correlation was observed also in patients (n=23) co-treated with typical
neuroleptics. Conversely, dose-concentration correlations were significant in either smoker or nonsmoker patients. No significant relationship between
body weight and
clozapine plasma parameters was reported. Further, we observed (1) a trend towards higher medians of
clozapine or total analytes in women than those reported in men (P=.09 and .07); (2) no significant difference in plasma levels obtained in subjects younger than 34 years and subjects 34 years old or older; (3) a trend towards higher
norclozapine and
clozapine plus
norclozapine levels (P=.05 and .08) in nonsmoker than smoker patients; (4) no significant difference between
clozapine plasma parameters measured in patients co-medicated with typical
neuroleptics and in patients receiving
clozapine alone.